• The document is an intimation and submission of an Investor Presentation pertaining to the financial performance for Q1 FY27 (ended June 30, 2026), filed pursuant to SEBI LODR Regulations.
  • The disclosure is made in continuation of a prior intimation dated August 17, 2026, regarding an Analysts/Investors Earning Call scheduled for August 21, 2026, at 03:00 P.M. (IST).
  • The stated purpose of the event is the discussion of the company's quarterly results.
  • The enclosed Investor Presentation includes the standalone financial performance for Q1 FY27 and FY26 (revised).
  • The presentation is made available on the company's website at https://www.orchidpharma.com/investors.
  • The document includes standard safe harbor language stating it contains forward-looking statements and is for informational purposes only.

Financial Highlights from Presentation (Q1 FY27 Standalone):

  • Revenue from Operations: ₹304 Cr (vs. ₹263 Cr in Q1 FY26; +16% YoY)
  • Other Income: ₹10 Cr (vs. ₹16 Cr in Q1 FY26; -38% YoY)
  • EBITDA: ₹25 Cr (vs. ₹9 Cr in Q1 FY26; +178% YoY); EBITDA Margin: 8% (vs. 3%)
  • PAT: ₹12 Cr (vs. Loss of ₹3 Cr in Q1 FY26)
  • Interest: ₹2 Cr
  • Depreciation: ₹11 Cr
  • Exceptional Items: ₹1 Cr

Full Year FY26 (Revised Standalone) Highlights:

  • Revenue from Operations: ₹1,233 Cr (vs. ₹1,397 Cr in FY25; -11% YoY)
  • EBITDA: ₹95 Cr (vs. ₹187 Cr in FY25; -49% YoY); EBITDA Margin: 8% (vs. 13%)
  • PAT: ₹35 Cr (vs. ₹132 Cr in FY25)

Strategic & Operational Context from Presentation:

  • The company highlights the completion of the amalgamation of Dhanuka Laboratories Ltd. into Orchid Pharma Ltd. under an NCLT-sanctioned scheme.
  • FY25 and FY26 results were revised from the 'Appointed Date' to reflect this amalgamation.
  • The company describes itself as "One of the most integrated anti-infective platform globally" and is "at an inflection point".

Additional Notes Section

  • The disclosure includes the enclosed Investor Presentation as an attachment.
  • The document contains financial data for Q1 FY27 and FY26.
  • It is signed by Kapil Dayya, Company Secretary & Compliance Officer.
  • The document contains extensive compliance references, including SEBI Regulation 30 and Circular No. SEBI/HO/49/14/14(7)2025-CFD-POD2/1/3762/2026 dated January 30, 2026.